Home › Trials › NCT04068597

Evaluating CCS1477 for blood cancers

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

PHASE1; PHASE2 · CellCentric Ltd. · NCT04068597

This study is testing a new drug called CCS1477 to see if it can help people with certain blood cancers who haven't responded to other treatments.

Quick facts

PhasePHASE1; PHASE2
Study typeInterventional
Enrollment250 (estimated)
Ages18 Years and up
SexAll
SponsorCellCentric Ltd. (industry)
Drugs / interventionschemotherapy
Locations39 sites (Atlanta, Georgia and 38 other locations)
Trial IDNCT04068597 on ClinicalTrials.gov

What this trial studies

This study assesses the safety, tolerability, pharmacokinetics, and biological activity of CCS1477 (inobrodib) in patients with various hematological malignancies, including Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, and higher-risk Myelodysplastic Syndrome. It involves patients who have relapsed or refractory conditions and have previously received standard therapies. The study will evaluate the effectiveness of CCS1477 in combination with other treatments such as Pomalidomide and Dexamethasone.

Who should consider this trial

Good fit: Ideal candidates include patients with confirmed relapsed or refractory hematological malignancies who have previously undergone standard therapy.

Not a fit: Patients currently receiving chemotherapy or other investigational agents may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with difficult-to-treat blood cancers.

How similar studies have performed: Other studies have shown promise in targeting similar hematological malignancies, suggesting potential for success with this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Provision of consent
* ECOG performance status 0-2
* Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
* Must have previously received standard therapy
* Adequate organ function

Exclusion Criteria:

* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
* Patients should discontinue statins prior to starting study treatment
* CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
* Any unresolved reversible toxicities from prior therapy \>CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
* Any evidence of severe or uncontrolled systemic diseases
* Any known uncontrolled inter-current illness
* QTcF prolongation (\> 470 msec)

Where this trial is running

Atlanta, Georgia and 38 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.